Focal brachytherapy for localized prostate cancer: Urinary toxicity depends on tumor location

Imagem de Miniatura
Arquivos
art_SROUGI_Focal_brachytherapy_for_localized_prostate_cancer_Urinary_toxicity_2017.PDF (466.58 KB)
Citações na Scopus
23
Tipo de produção
article
Data de publicação
2017
Editora
ELSEVIER SCIENCE INC
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
BARRET, Eric
NUNES-SILVA, Igor
BAGHDADI, Mohammed
GARCIA-BARRERAS, Silvia
PIERRAT, Noelle
ROZET, Francois
GALIANO, Marc
SANCHEZ-SALAS, Rafael
CATHELINEAU, Xavier
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
BRACHYTHERAPY, v.16, n.5, p.988-992, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
PURPOSE: To evaluate whether patients with prostate cancer have worse functional urinary recovery with focal brachytherapy (FBT) at the base versus the apex of the prostate. METHODS AND MATERIALS: The functional outcomes of patients treated with FBT at the base of the prostate were compared with those of patients treated with FBT at the apex. Urinary symptoms, continence, and erectile dysfunction were measured using the International Prostate Symptom Score (IPSS), International Continence Score (ICS), and International Index of Erectile Function (IIEF-5) questionnaires, respectively, at baseline and at 6, 12, and 24 months after treatment. RESULTS: Twenty-eight and 13 patients were treated with FBT at the apex and the base, respectively, of the prostate. A significant difference between groups was found in the IPSS score at 6 months (mean IPSS: apex 6.4 +/- 4.7, base 10.6 +/- 5.7; p = 0.02), but not at baseline or at 12 and 24 months after treatment. On multivariate analysis, only FBT at the base of the prostate remained an independent predictor of worsening urinary symptoms (odds ratio, 5.8; p = 0.04). CONCLUSIONS: At 6 months after FBT, significantly less urinary toxicity was found in patients who underwent FBT at the apex versus the base of the prostate. Continence and sexual side effects were minimal in all patients.
Palavras-chave
Prostate cancer, Focal therapy, Brachytherapy, Urinary toxicity, Urinary symptoms
URI
https://observatorio.fm.usp.br/handle/OPI/24409
Referências
  1. Ahmed HU, 2009, NEW ENGL J MED, V361, P1704, DOI 10.1056/NEJMcibr0905562
  2. Anscher MS, 2005, INT J RADIAT ONCOL, V62, P255, DOI 10.1016/j.ijrobp.2005.01.040
  3. Bittner N, 2008, UROLOGY, V71, P460, DOI 10.1016/j.urology.2007.10.023
  4. Blaivas JG, 2006, BJU INT, V98, P1233, DOI 10.1111/j.1464-410X.2006.06491.x
  5. Buron C, 2007, INT J RADIAT ONCOL, V67, P812, DOI 10.1016/j.ijrobp.2006.10.011
  6. Chuang YC, 2008, BJU INT, V102, P704, DOI 10.1111/j.1464-410X.2008.07740.x
  7. Cosset JM, 2016, CANCER RADIOTHER, V20, P261, DOI 10.1016/j.canrad.2016.02.009
  8. Cosset JM, 2013, BRACHYTHERAPY, V12, P331, DOI 10.1016/j.brachy.2013.02.002
  9. Crawford ED, 2006, AM J CLIN ONCOL-CANC, V29, P517, DOI 10.1097/01.coc.0000225412.24750.4c
  10. Crook J, 2008, J UROLOGY, V179, P141, DOI 10.1016/j.juro.2007.08.136
  11. Earley JJ, 2012, RADIOTHER ONCOL, V104, P187, DOI 10.1016/j.radonc.2012.06.001
  12. Elshaikh MA, 2005, INT J RADIAT ONCOL, V62, P164, DOI 10.1016/j.ijrobp.2004.09.036
  13. Ghadjar P, 2014, INT J RADIAT ONCOL, V88, P339, DOI 10.1016/j.ijrobp.2013.10.042
  14. Hathout L, 2014, INT J RADIAT ONCOL, V90, P312, DOI 10.1016/j.ijrobp.2014.06.031
  15. Hinnen KA, 2011, BJU INT, V107, P1906, DOI 10.1111/j.1464-410X.2010.09769.x
  16. Hinnen KA, 2010, INT J RADIAT ONCOL, V76, P1433, DOI 10.1016/j.ijrobp.2009.03.049
  17. Jereczek-Fossa BA, 2016, CRIT REV ONCOL HEMAT, V105, P100, DOI 10.1016/j.critrevonc.2016.06.010
  18. Keyes M, 2006, INT J RADIAT ONCOL, V64, P825, DOI 10.1016/j.ijrobp.2005.04.056
  19. Keyes M, 2012, BRACHYTHERAPY, V11, P199, DOI 10.1016/j.brachy.2011.05.007
  20. Kragelj B, 2016, RADIOL ONCOL, V50, P94, DOI 10.1515/raon-2015-0010
  21. Mueller A, 2004, INT J RADIAT ONCOL, V59, P1047, DOI 10.1016/j.ijrobp.2003.12.016
  22. Nguyen PL, 2012, J UROLOGY, V188, P1151, DOI 10.1016/j.juro.2012.06.010
  23. Ots AF, 2016, JMIR RES PROTOC, V5, DOI 10.2196/resprot.5433
  24. Punnen S, 2015, EUR UROL, V68, P600, DOI 10.1016/j.eururo.2014.08.074
  25. Roosen A, 2009, EUR UROL, V56, P346, DOI 10.1016/j.eururo.2008.06.048
  26. Sanchez-Gomez LM, 2017, ACTAS UROL ESP, V41, P71, DOI 10.1016/j.acuro.2016.06.001
  27. Shimizu N, 2014, WORLD J UROL, V32, P1423, DOI 10.1007/s00345-014-1239-z
  28. Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
  29. Stock RG, 2006, INT J RADIAT ONCOL, V64, P810, DOI 10.1016/j.ijrobp.2005.09.005
  30. Stone NN, 2007, J UROLOGY, V177, P925, DOI 10.1016/j.juro.2006.10.018
  31. Tward JD, 2016, INT J RADIAT ONCOL, V95, P1443, DOI 10.1016/j.ijrobp.2016.03.047
  32. Zelefsky MJ, 2012, BRACHYTHERAPY, V11, P245, DOI 10.1016/j.brachy.2011.08.003

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - ODS/03